Cortexyme Inc (CRTX) Stock
CRTX is no longer traded. Cortexyme was delisted from the Nasdaq in September 2022.
Prices on this page are historical; the last trade was September 30, 2022 at $1.33.
Cortexyme stock price history
CRTX final trading statistics
- Final close
- $1.33
- Final trading day
- Sep 30, 2022
- Market cap at delisting
- $48.08M
- Shares outstanding
- 36.15M
- Final 52-week range
- $1.20 – $98.50
- Avg. volume (final 3 mo.)
- 251,430
- All-time high (split-adj.)
- $120.21 · Aug 2021
- All-time low (split-adj.)
- $0.16 · Sep 2008
- Return since IPO
- -81.3%
- Beta
- 1.40
- Book value / share
- $3.53
- Price / book
- 0.38
Cortexyme annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$89.9M | -$3.01 |
| FY2020 | $0.00 | -$76.8M | -$2.63 |
| FY2019 | $0.00 | -$37.0M | -$2.56 |
| FY2018 | $0.00 | -$12.5M | — |
| FY2017 | $0.00 | -$12.2M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Cortexyme Inc
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Cortexyme stock FAQ
What happened to Cortexyme stock?
Cortexyme stock was delisted from the Nasdaq. Its final close was $1.33 on September 30, 2022.
Is CRTX stock still trading?
No. CRTX was delisted from the Nasdaq in September 2022 and no longer trades on a U.S. exchange.
What was the last price of CRTX stock?
CRTX closed at $1.33 on its final trading day, September 30, 2022, for a market value of about $48.08M.
What were Cortexyme's revenue and earnings in its last full fiscal year?
Cortexyme reported revenue of $0.00 and net income of -$89.9M in fiscal 2021, its last full year as a public company.
When did Cortexyme go public?
Cortexyme Inc stock began trading on May 9, 2019.